Skip to main content

Table 1 Correlation between PRL-3 gene amplification and clinicopathological variables in 77 patients with gastric cancer

From: Therapeutic potential of PRL-3 targeting and clinical significance of PRL-3 genomic amplification in gastric cancer

   PRL-3 gene amplification  
Variables Total number Negativity Positivity pvalue
   Number (%) Number (%)  
PRL-3 expression       0.006
Negativity 37 37 (100) 0 (0)  
Positivity 40 32 (80) 8 (20)  
Age (years)       0.726
<60 34 30 (88) 4 (12)  
≥60 43 39 (91) 4 (9)  
Gender       0.710
Male 51 45 (88) 6 (12)  
Female 26 24 (92) 2 (8)  
Lymphatic permeation       0.343
Absence 15 15 (100) 0 (0)  
Presence 62 54 (87) 8 (13)  
Vascular permeation       0.263
Absence 25 24 (96) 1 (4)  
Presence 52 45 (87) 7 (13)  
Differentiation       0.134
Well and moderate 31 30 (97) 1 (3)  
Poor 46 39 (85) 7 (15)  
Depth of invasion       0.006*
T1 (m and sm) 15 15 (100) 0 (0)  
T2 (mp and ss) 35 33 (94) 2 (6)  
T3 (se) 19 16 (84) 3 (16)  
T4 (si) 8 5 (63) 3 (38)  
Lymph node metastasis       0.022
Absence 29 29 (100) 0 (0)  
Presence 48 40 (83) 8 (17)  
JCGC lymph node status       0.004*
N0 29 29 (100) 0 (0)  
N1 21 20 (95) 1 (5)  
N2 20 14 (70) 6 (30)  
N3 and distant lymph nodes 7 6 (86) 1 (14)  
UICC lymph node status       0.002*
N0 29 29 (100) 0 (0)  
N1 18 17 (94) 1 (6)  
N2 16 13 (81) 3 (19)  
N3 and distant lymph nodes 14 10 (71) 4 (29)  
JCGC stage       0.005*
I (IA and IB) 20 20 (100) 0 (0)  
II 20 20 (100) 0 (0)  
III (IIIA and IIIB) 19 15 (79) 4 (21)  
IV 18 14 (78) 4 (22)  
UICC stage       0.003*
I (IA and IB) 21 21 (100) 0 (0)  
II 20 20 (100) 0 (0)  
III (IIIA and IIIB) 16 13 (81) 3 (19)  
IV 20 15 (75) 5 (25)